LATEST NEWS

Hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy for the treatment of frail and/or elderly patients with locally advanced HNSCC: a phase I/II study

For inquiries about our technology, collaborations, clinical trials, or other topics, we encourage you to get in touch with our team.